fluorodeoxyglucose f18 has been researched along with Dyskinesia, Drug-Induced in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Loane, C; Niccolini, F; Politis, M | 1 |
| Lewitt, PA; Mouradian, MM | 1 |
| Koenig, G; Leventhal, L; Masilamoni, GJ; Papa, SM; Uthayathas, S | 1 |
| Eidelberg, D; Feigin, A; Niethammer, M | 1 |
| Gitlin, JD; Goldman, S; Haemers, I; Kono, S; Pandolfo, M | 1 |
| Hirato, M; Horikoshi, S; Ishihara, J; Ohye, C; Shibazaki, T | 1 |
| Gallacher, F; Gur, RC; Gur, RE; Mozley, LH; Szymanski, S | 1 |
2 review(s) available for fluorodeoxyglucose f18 and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Dyskinesias in Parkinson's disease: views from positron emission tomography studies.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Fluorodeoxyglucose F18; Humans; Levodopa; Parkinson Disease; Positron-Emission Tomography | 2014 |
Functional neuroimaging in Parkinson's disease.
Topics: Antiparkinson Agents; Brain Diseases, Metabolic; Cognition Disorders; Disease Progression; Dopamine; Dyskinesia, Drug-Induced; Fluorodeoxyglucose F18; Functional Neuroimaging; Humans; Levodopa; Lewy Bodies; Magnetic Resonance Imaging; Neurotransmitter Agents; Parkinson Disease; Positron-Emission Tomography; Psychomotor Disorders; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2012 |
5 other study(ies) available for fluorodeoxyglucose f18 and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism?
Topics: Amantadine; Antiparasitic Agents; Dyskinesia, Drug-Induced; Fluorodeoxyglucose F18; Humans; Levodopa; Parkinson Disease; Positron-Emission Tomography; Presynaptic Terminals | 2014 |
Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile.
Topics: Animals; Antipsychotic Agents; Brain; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Fluorodeoxyglucose F18; Macaca mulatta; Male; Motor Skills; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Positron-Emission Tomography; Radiopharmaceuticals; Schizophrenia | 2016 |
Clinical, molecular, and PET study of a case of aceruloplasminaemia presenting with focal cranial dyskinesia.
Topics: Brain; Ceruloplasmin; Diagnosis, Differential; DNA Mutational Analysis; Dyskinesia, Drug-Induced; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Middle Aged; Point Mutation; Radiopharmaceuticals; Tomography, Emission-Computed | 2004 |
Parkinsonian rigidity, dopa-induced dyskinesia and chorea--dynamic studies on the basal ganglia-thalamocortical motor circuit using PET scan and depth microrecording.
Topics: Antiparkinson Agents; Basal Ganglia; Blood Glucose; Brain; Brain Mapping; Cerebral Cortex; Chorea; Deoxyglucose; Dyskinesia, Drug-Induced; Electrodes, Implanted; Energy Metabolism; Fluorodeoxyglucose F18; Globus Pallidus; Humans; Levodopa; Motor Neurons; Neural Pathways; Neurologic Examination; Parkinson Disease; Stereotaxic Techniques; Thalamic Nuclei; Tomography, Emission-Computed; Tremor | 1995 |
Vulnerability to tardive dyskinesia development in schizophrenia: an FDG-PET study of cerebral metabolism.
Topics: Adult; Brain; Deoxyglucose; Disease Susceptibility; Dyskinesia, Drug-Induced; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Schizophrenia; Tomography, Emission-Computed | 1996 |